Gapping down
In reaction to earnings/guidance:
- ACB -0.5% (guidance update)
Select ETFs showing early weakness:
- XLK -3.5%, QQQ -3.4%, SMH -3.2%, IGV -2.3%
Other news:
- CRBP -73% (announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic sclerosis)
- TTWO -17.2% (files for 603,817 share common stock offering by selling shareholders)
- SBBP -15.6% (positive and statistically significant top-line results from the pivotal phase 3 Logics study of Recorlev for the treatment of endogenous cushing's syndrome)
- TSLA -13.2% (not added to S&P 500 (expectation that it would))
- DOCU -5.5% (may be related to lack of inclusion in S&P 500)
- RIG -4.5% (files for 67,696,498 share common stock offering by selling shareholder)
- ZM -4.3% (cautious article in Barrons; also - may be related to lack of inclusion in S&P 500)
- FOUR -3.1% (transaction update)
- GERN -1.6% (files for $350 mln mixed securities shelf offering)
Analyst comments:
- NOK -5.4% (downgraded to Mkt Perform from Strong Buy at Raymond James)
- DSX -4.2% (downgraded to Hold from Buy at Pareto)
- PAGS -3.2% (downgraded to Neutral from Buy at Goldman)
- FAST -2.9% (downgraded to Underperform from Mkt Perform at Raymond James)
- WYNN -2.5% (downgraded to Neutral from Buy at Goldman and removed from Conviction Buy List)
- ROP -1.7% (downgraded to Underweight from Neutral at JP Morgan)